Headlines about Utah Medical Products (NASDAQ:UTMD) have been trending somewhat positive on Tuesday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Utah Medical Products earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media stories about the medical instruments supplier an impact score of 45.7511027481739 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news articles that may have impacted Accern’s rankings:
- Utah Medical Products, Inc. (UTMD) CEO Sells $99,655.95 in Stock (americanbankingnews.com)
- Anne Arundel County Police Use DNA Snapshot to Aid Identification of Baltimore Murder Victim, Leading to Arrest and Confession (officer.com)
- Co-Diagnostics, Inc. Ships Product to India for Validation Study (wallstreet-online.de)
- Utah Medical Products, Inc. (UTMD) CEO Kevin L. Cornwell Sells 150 Shares (americanbankingnews.com)
Shares of Utah Medical Products (NASDAQ UTMD) opened at $90.35 on Tuesday. Utah Medical Products has a 12 month low of $58.50 and a 12 month high of $94.00. The company has a market cap of $336.16, a P/E ratio of 24.55 and a beta of 0.77.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 3rd. Shareholders of record on Friday, March 16th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 1.20%. The ex-dividend date of this dividend is Thursday, March 15th. Utah Medical Products’s payout ratio is 29.35%.
Separately, BidaskClub raised shares of Utah Medical Products from a “hold” rating to a “buy” rating in a research report on Wednesday, December 6th.
In related news, Director Ernst G. Hoyer sold 1,529 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $88.08, for a total value of $134,674.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin L. Cornwell sold 1,095 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $91.01, for a total transaction of $99,655.95. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 8,035 shares of company stock valued at $716,900. Company insiders own 9.10% of the company’s stock.
Utah Medical Products Company Profile
Utah Medical Products, Inc (UTMD) is engaged in the business of producing medical devices that are disposable and for hospital use. The Company’s product categories include labor and delivery/obstetrics, including fetal monitoring accessories, Vacuum-Assisted Delivery Systems (VAD), and other labor and delivery tools; neonatal intensive care, including DISPOSA-HOOD, DELTRAN PLUS and GESCO; gynecology/urology/electrosurgery, including LETZ System, FINESSE+ Generator, EPITOME, PATHFINDER PLUS, HOLMIUM LASER FIBRES, LIBERTY System, ENDOCURETTE, TVUS/HSG-Cath and LUMIN, and blood pressure monitoring, including DELTRAN Disposable Pressure Transducer (DPT), and pressure monitoring accessories, components and other molded parts.
Receive News & Ratings for Utah Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Utah Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.